Dermira, Inc. (NASDAQ:DERM) insider Eugene A. Bauer sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Dermira, Inc. (DERM) opened at 29.03 on Friday. The firm’s market capitalization is $1.21 billion. The stock has a 50 day moving average price of $26.17 and a 200-day moving average price of $28.39. Dermira, Inc. has a 52 week low of $21.35 and a 52 week high of $38.75.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.04). Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.00 million. On average, analysts anticipate that Dermira, Inc. will post ($4.20) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Eugene A. Bauer Sells 7,500 Shares of Dermira, Inc. (DERM) Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/15/eugene-a-bauer-sells-7500-shares-of-dermira-inc-derm-stock.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Dermira by 15.6% in the 2nd quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock valued at $114,294,000 after purchasing an additional 529,405 shares in the last quarter. Jennison Associates LLC increased its stake in Dermira by 16.7% in the 2nd quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock valued at $76,725,000 after purchasing an additional 377,554 shares in the last quarter. Vanguard Group Inc. increased its stake in Dermira by 9.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after purchasing an additional 125,157 shares in the last quarter. Voya Investment Management LLC increased its stake in Dermira by 61.4% in the 2nd quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after purchasing an additional 467,356 shares in the last quarter. Finally, State Street Corp increased its stake in Dermira by 38.4% in the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after purchasing an additional 228,093 shares in the last quarter. 97.56% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have recently commented on DERM. BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Mizuho restated a “buy” rating and issued a $43.00 price objective (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Cantor Fitzgerald began coverage on Dermira in a research report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price objective for the company. Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Evercore ISI assumed coverage on Dermira in a research note on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $44.40.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.